25 XP   0   0   10

Pyxis Oncology Inc
Buy, Hold or Sell?

Let's analyse Pyxis Oncology Inc together

PenkeI guess you are interested in Pyxis Oncology Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Pyxis Oncology Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Pyxis Oncology Inc

I send you an email if I find something interesting about Pyxis Oncology Inc.

Quick analysis of Pyxis Oncology Inc (30 sec.)










What can you expect buying and holding a share of Pyxis Oncology Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.16
Expected worth in 1 year
$1.56
How sure are you?
7.7%

+ What do you gain per year?

Total Gains per Share
$-0.60
Return On Investment
-12.5%

For what price can you sell your share?

Current Price per Share
$4.83
Expected price per share
$2.87 - $6.92
How sure are you?
50%

1. Valuation of Pyxis Oncology Inc (5 min.)




Live pricePrice per Share (EOD)

$4.83

Intrinsic Value Per Share

$-18.72 - $-22.03

Total Value Per Share

$-16.56 - $-19.86

2. Growth of Pyxis Oncology Inc (5 min.)




Is Pyxis Oncology Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$125.7m$198.7m-$58.4m-41.7%

How much money is Pyxis Oncology Inc making?

Current yearPrevious yearGrowGrow %
Making money-$18m-$15.2m-$2.8m-15.6%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Pyxis Oncology Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#338 / 1019

Most Revenue
#734 / 1019

Most Profit
#678 / 1019

Most Efficient
#277 / 1019

What can you expect buying and holding a share of Pyxis Oncology Inc? (5 min.)

Welcome investor! Pyxis Oncology Inc's management wants to use your money to grow the business. In return you get a share of Pyxis Oncology Inc.

What can you expect buying and holding a share of Pyxis Oncology Inc?

First you should know what it really means to hold a share of Pyxis Oncology Inc. And how you can make/lose money.

Speculation

The Price per Share of Pyxis Oncology Inc is $4.83. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Pyxis Oncology Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Pyxis Oncology Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.16. Based on the TTM, the Book Value Change Per Share is $-0.15 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.43 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Pyxis Oncology Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.27-5.6%-0.32-6.6%-0.43-8.9%-0.36-7.4%-0.36-7.4%
Usd Book Value Change Per Share-0.21-4.4%-0.15-3.1%-0.43-8.9%0.173.4%0.173.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.21-4.4%-0.15-3.1%-0.43-8.9%0.173.4%0.173.4%
Usd Price Per Share1.80-2.59-2.43-2.39-2.39-
Price to Earnings Ratio-1.68--2.08--1.37--1.79--1.79-
Price-to-Total Gains Ratio-8.55--18.21--5.65--10.39--10.39-
Price to Book Ratio0.83-1.06-0.69-0.72-0.72-
Price-to-Total Gains Ratio-8.55--18.21--5.65--10.39--10.39-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.83
Number of shares207
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.150.17
Usd Total Gains Per Share-0.150.17
Gains per Quarter (207 shares)-31.2634.43
Gains per Year (207 shares)-125.05137.72
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-125-1350138128
20-250-2600275266
30-375-3850413404
40-500-5100551542
50-625-6350689680
60-750-7600826818
70-875-8850964956
80-1000-1010011021094
90-1125-1135012401232
100-1251-1260013771370

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.013.00.00.0%0.013.00.00.0%0.013.00.00.0%
Book Value Change Per Share0.04.00.00.0%1.010.01.08.3%1.011.01.07.7%1.011.01.07.7%1.011.01.07.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.013.00.0%0.00.013.00.0%0.00.013.00.0%
Total Gains per Share0.04.00.00.0%1.010.01.08.3%1.011.01.07.7%1.011.01.07.7%1.011.01.07.7%

Fundamentals of Pyxis Oncology Inc

About Pyxis Oncology Inc

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-03-31 11:38:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Pyxis Oncology Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Pyxis Oncology Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Pyxis Oncology Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Pyxis Oncology Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--197.2%+197.2%
TTM--210.4%+210.4%
YOY--279.3%+279.3%
5Y--436.8%+436.8%
10Y--599.3%+599.3%
1.1.2. Return on Assets

Shows how efficient Pyxis Oncology Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Pyxis Oncology Inc to the Biotechnology industry mean.
  • -9.0% Return on Assets means that Pyxis Oncology Inc generated $-0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Pyxis Oncology Inc:

  • The MRQ is -9.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.0%TTM-10.0%+1.0%
TTM-10.0%YOY-6.0%-4.0%
TTM-10.0%5Y-38.0%+28.0%
5Y-38.0%10Y-38.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.0%-13.6%+4.6%
TTM-10.0%-12.9%+2.9%
YOY-6.0%-11.9%+5.9%
5Y-38.0%-14.2%-23.8%
10Y-38.0%-16.2%-21.8%
1.1.3. Return on Equity

Shows how efficient Pyxis Oncology Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Pyxis Oncology Inc to the Biotechnology industry mean.
  • -12.4% Return on Equity means Pyxis Oncology Inc generated $-0.12 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Pyxis Oncology Inc:

  • The MRQ is -12.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -12.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.4%TTM-12.9%+0.5%
TTM-12.9%YOY-6.4%-6.5%
TTM-12.9%5Y-6.4%-6.5%
5Y-6.4%10Y-6.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.4%-17.0%+4.6%
TTM-12.9%-16.1%+3.2%
YOY-6.4%-15.4%+9.0%
5Y-6.4%-20.0%+13.6%
10Y-6.4%-21.1%+14.7%

1.2. Operating Efficiency of Pyxis Oncology Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Pyxis Oncology Inc is operating .

  • Measures how much profit Pyxis Oncology Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Pyxis Oncology Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Pyxis Oncology Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM--224.4%+224.4%
YOY--288.4%+288.4%
5Y--475.2%+475.2%
10Y--624.7%+624.7%
1.2.2. Operating Ratio

Measures how efficient Pyxis Oncology Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Pyxis Oncology Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.997-2.997
TTM-3.247-3.247
YOY-3.766-3.766
5Y-5.675-5.675
10Y-7.857-7.857

1.3. Liquidity of Pyxis Oncology Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Pyxis Oncology Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.84 means the company has $4.84 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Pyxis Oncology Inc:

  • The MRQ is 4.837. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.849. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.837TTM9.849-5.011
TTM9.849YOY11.202-1.353
TTM9.8495Y11.020-1.171
5Y11.02010Y11.0200.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.8373.930+0.907
TTM9.8494.251+5.598
YOY11.2025.436+5.766
5Y11.0206.045+4.975
10Y11.0206.363+4.657
1.3.2. Quick Ratio

Measures if Pyxis Oncology Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Pyxis Oncology Inc to the Biotechnology industry mean.
  • A Quick Ratio of 8.95 means the company can pay off $8.95 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Pyxis Oncology Inc:

  • The MRQ is 8.945. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 16.777. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ8.945TTM16.777-7.832
TTM16.777YOY10.984+5.793
TTM16.7775Y11.753+5.024
5Y11.75310Y11.7530.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.9453.629+5.316
TTM16.7774.065+12.712
YOY10.9845.397+5.587
5Y11.7535.993+5.760
10Y11.7536.277+5.476

1.4. Solvency of Pyxis Oncology Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Pyxis Oncology Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Pyxis Oncology Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.28 means that Pyxis Oncology Inc assets are financed with 27.6% credit (debt) and the remaining percentage (100% - 27.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Pyxis Oncology Inc:

  • The MRQ is 0.276. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.219. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.276TTM0.219+0.057
TTM0.219YOY0.150+0.069
TTM0.2195Y0.733-0.514
5Y0.73310Y0.7330.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2760.332-0.056
TTM0.2190.334-0.115
YOY0.1500.268-0.118
5Y0.7330.366+0.367
10Y0.7330.390+0.343
1.4.2. Debt to Equity Ratio

Measures if Pyxis Oncology Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Pyxis Oncology Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 38.2% means that company has $0.38 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Pyxis Oncology Inc:

  • The MRQ is 0.382. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.286. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.382TTM0.286+0.096
TTM0.286YOY0.182+0.104
TTM0.2865Y0.149+0.136
5Y0.14910Y0.1490.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3820.381+0.001
TTM0.2860.390-0.104
YOY0.1820.334-0.152
5Y0.1490.434-0.285
10Y0.1490.466-0.317

2. Market Valuation of Pyxis Oncology Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Pyxis Oncology Inc generates.

  • Above 15 is considered overpriced but always compare Pyxis Oncology Inc to the Biotechnology industry mean.
  • A PE ratio of -1.68 means the investor is paying $-1.68 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Pyxis Oncology Inc:

  • The EOD is -4.501. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.677. Based on the earnings, the company is expensive. -2
  • The TTM is -2.075. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.501MRQ-1.677-2.823
MRQ-1.677TTM-2.075+0.398
TTM-2.075YOY-1.371-0.704
TTM-2.0755Y-1.789-0.286
5Y-1.78910Y-1.7890.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.501-2.315-2.186
MRQ-1.677-2.560+0.883
TTM-2.075-2.664+0.589
YOY-1.371-4.122+2.751
5Y-1.789-6.258+4.469
10Y-1.789-6.108+4.319
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Pyxis Oncology Inc:

  • The EOD is -4.602. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.715. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.005. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.602MRQ-1.715-2.887
MRQ-1.715TTM-2.005+0.290
TTM-2.005YOY-1.432-0.573
TTM-2.0055Y-2.033+0.028
5Y-2.03310Y-2.0330.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.602-3.067-1.535
MRQ-1.715-3.251+1.536
TTM-2.005-3.545+1.540
YOY-1.432-5.595+4.163
5Y-2.033-8.315+6.282
10Y-2.033-8.708+6.675
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Pyxis Oncology Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.83 means the investor is paying $0.83 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Pyxis Oncology Inc:

  • The EOD is 2.234. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.832. Based on the equity, the company is cheap. +2
  • The TTM is 1.057. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.234MRQ0.832+1.401
MRQ0.832TTM1.057-0.224
TTM1.057YOY0.687+0.369
TTM1.0575Y0.724+0.332
5Y0.72410Y0.7240.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.2341.905+0.329
MRQ0.8322.111-1.279
TTM1.0572.095-1.038
YOY0.6872.836-2.149
5Y0.7243.443-2.719
10Y0.7243.794-3.070
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Pyxis Oncology Inc.

3.1. Institutions holding Pyxis Oncology Inc

Institutions are holding 29.844% of the shares of Pyxis Oncology Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30LAURION CAPITAL MANAGEMENT LP7.15380.0385317080300
2023-12-31Vanguard Group Inc2.94810.0001130668516644214.5971
2023-12-31abrdn PLC1.5980.00287083037083030
2023-12-31Vestal Point Capital LP0.99270.08394400004400000
2023-12-31Hillhouse Capital Advisors, Ltd.0.86320.013938260600
2023-12-31Renaissance Technologies Corp0.82160.00136415014789968.3923
2023-12-31Decheng Capital LLC0.73730.16443268103268100
2023-12-31BlackRock Inc0.7008031059890843.0128
2023-12-31Geode Capital Management, LLC0.69540.0001308241199426.9171
2023-12-31Bridgeway Capital Management, LLC0.53290.009123619500
2023-12-31Deutsche Bank AG0.2820.000112500000
2023-12-31Harvest Investment Services, LLC0.25250.0928111937-1957-1.7183
2023-12-31Dimensional Fund Advisors, Inc.0.22970.0001101810-51961-33.7912
2023-12-31Two Sigma Investments LLC0.20660.000491563-28250-23.5784
2023-12-31State Street Corporation0.187408305500
2023-12-31Cornercap Investment Counsel Inc.0.1690.02217490300
2023-12-31Yu Fan0.15640.62526930300
2023-12-31Two Sigma Advisers, LLC0.14480.000364200-16300-20.2484
2023-12-31Cable Car Capital LLC0.1390.115161606616060
2023-12-31Northern Trust Corp0.136060283753714.2892
Total 18.94721.16998398051+1789155+21.3%

3.2. Funds holding Pyxis Oncology Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.01970.000490392300
2023-12-31HBM Healthcare Investments AG Ord1.60390.064771782300
2024-02-29abrdn Healthcare Investors1.07620.305848164600
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.9860.00284412645487914.2032
2024-02-29abrdn Life Sciences Investors0.50640.325922665700
2024-01-31Fidelity Extended Market Index0.39810.001917815800
2024-01-31DWS ESG Biotech LC0.27930.131212500300
2023-12-31Bridgeway Ultra-Small Company Market0.26880.116512029500
2023-12-31Bridgeway Ultra-Small Company0.2590.240711590000
2023-09-30BlackRock Extended Mkt Composite0.17940.00118030100
2024-02-29iShares Micro-Cap ETF0.17580.05497868200
2023-12-31BlackRock Extended Equity Market K0.15650.000970056-141-0.2009
2024-01-31Fidelity Total Market Index0.11290.00025054400
2024-01-31DFA US Targeted Value I0.10180.00144557800
2024-01-31Fidelity Series Total Market Index0.09310.000341680984130.9086
2023-12-31CornerCap Small-Cap Value Advisor0.08210.04983673700
2023-12-31CornerCap Fundametrics Small0.08210.04973673700
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.06360.00082847300
2023-12-31NT Ext Equity Mkt Idx Fd - L0.06190.000927709574726.1679
2023-12-31Northern Trust Extended Eq Market Idx0.06190.000927709574726.1679
Total 8.56851.35083834875+76073+2.0%

3.3. Insider Transactions

Insiders are holding 21.968% of the shares of Pyxis Oncology Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-09-27Jitendra WadhaneBUY25001.87
2023-09-27Pamela Ann ConnealyBUY64261.85
2023-09-25Jitendra WadhaneBUY50001.77
2023-09-25Pamela Ann ConnealyBUY120001.67
2023-09-22Jitendra WadhaneBUY25001.74
2023-09-22Pamela Ann ConnealyBUY50001.74
2023-09-18Lara SullivanSELL85412.1
2023-09-13Lara SullivanSELL30002.27
2023-09-11Lara SullivanSELL200002.27

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Pyxis Oncology Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.211-0.151-28%-0.432+105%0.166-227%0.166-227%
Book Value Per Share--2.1622.413-10%3.419-37%1.928+12%1.928+12%
Current Ratio--4.8379.849-51%11.202-57%11.020-56%11.020-56%
Debt To Asset Ratio--0.2760.219+26%0.150+85%0.733-62%0.733-62%
Debt To Equity Ratio--0.3820.286+34%0.182+110%0.149+156%0.149+156%
Dividend Per Share----0%-0%-0%-0%
Eps---0.268-0.317+18%-0.432+61%-0.356+33%-0.356+33%
Free Cash Flow Per Share---0.262-0.333+27%-0.412+57%-0.281+7%-0.281+7%
Free Cash Flow To Equity Per Share---0.263-0.281+7%-0.410+56%0.137-291%0.137-291%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---22.026--------
Intrinsic Value_10Y_min---18.718--------
Intrinsic Value_1Y_max---1.348--------
Intrinsic Value_1Y_min---1.324--------
Intrinsic Value_3Y_max---4.706--------
Intrinsic Value_3Y_min---4.479--------
Intrinsic Value_5Y_max---8.852--------
Intrinsic Value_5Y_min---8.160--------
Market Cap280784322.000+63%104640120.000150565506.000-31%141409495.500-26%138894108.000-25%138894108.000-25%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio2.234+63%0.8321.057-21%0.687+21%0.724+15%0.724+15%
Pe Ratio-4.501-168%-1.677-2.075+24%-1.371-18%-1.789+7%-1.789+7%
Price Per Share4.830+63%1.8002.590-31%2.433-26%2.389-25%2.389-25%
Price To Free Cash Flow Ratio-4.602-168%-1.715-2.005+17%-1.432-17%-2.033+19%-2.033+19%
Price To Total Gains Ratio-22.936-168%-8.548-18.213+113%-5.648-34%-10.392+22%-10.392+22%
Quick Ratio--8.94516.777-47%10.984-19%11.753-24%11.753-24%
Return On Assets---0.090-0.100+11%-0.060-33%-0.380+323%-0.380+323%
Return On Equity---0.124-0.129+4%-0.064-49%-0.064-48%-0.064-48%
Total Gains Per Share---0.211-0.151-28%-0.432+105%0.166-227%0.166-227%
Usd Book Value--125704000.000140272000.000-10%198762750.000-37%112087307.692+12%112087307.692+12%
Usd Book Value Change Per Share---0.211-0.151-28%-0.432+105%0.166-227%0.166-227%
Usd Book Value Per Share--2.1622.413-10%3.419-37%1.928+12%1.928+12%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.268-0.317+18%-0.432+61%-0.356+33%-0.356+33%
Usd Free Cash Flow---15254000.000-19358750.000+27%-23933500.000+57%-16354076.923+7%-16354076.923+7%
Usd Free Cash Flow Per Share---0.262-0.333+27%-0.412+57%-0.281+7%-0.281+7%
Usd Free Cash Flow To Equity Per Share---0.263-0.281+7%-0.410+56%0.137-291%0.137-291%
Usd Market Cap280784322.000+63%104640120.000150565506.000-31%141409495.500-26%138894108.000-25%138894108.000-25%
Usd Price Per Share4.830+63%1.8002.590-31%2.433-26%2.389-25%2.389-25%
Usd Profit---15597000.000-18019750.000+16%-15209500.000-2%-16420846.154+5%-16420846.154+5%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.211-0.151-28%-0.432+105%0.166-227%0.166-227%
 EOD+5 -3MRQTTM+13 -16YOY+14 -155Y+13 -1610Y+13 -16

4.2. Fundamental Score

Let's check the fundamental score of Pyxis Oncology Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.501
Price to Book Ratio (EOD)Between0-12.234
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than18.945
Current Ratio (MRQ)Greater than14.837
Debt to Asset Ratio (MRQ)Less than10.276
Debt to Equity Ratio (MRQ)Less than10.382
Return on Equity (MRQ)Greater than0.15-0.124
Return on Assets (MRQ)Greater than0.05-0.090
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Pyxis Oncology Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.825
Ma 20Greater thanMa 504.856
Ma 50Greater thanMa 1005.116
Ma 100Greater thanMa 2003.676
OpenGreater thanClose4.740
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets173,726
Total Liabilities48,022
Total Stockholder Equity125,704
 As reported
Total Liabilities 48,022
Total Stockholder Equity+ 125,704
Total Assets = 173,726

Assets

Total Assets173,726
Total Current Assets124,604
Long-term Assets49,122
Total Current Assets
Cash And Cash Equivalents 11,136
Short-term Investments 109,634
Net Receivables 21
Other Current Assets 3,813
Total Current Assets  (as reported)124,604
Total Current Assets  (calculated)124,604
+/-0
Long-term Assets
Property Plant Equipment 24,814
Intangible Assets 24,308
Long-term Assets  (as reported)49,122
Long-term Assets  (calculated)49,122
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities25,759
Long-term Liabilities22,263
Total Stockholder Equity125,704
Total Current Liabilities
Short-term Debt 1,232
Accounts payable 3,896
Other Current Liabilities 12,971
Total Current Liabilities  (as reported)25,759
Total Current Liabilities  (calculated)18,099
+/- 7,660
Long-term Liabilities
Capital Lease Obligations 21,331
Long-term Liabilities  (as reported)22,263
Long-term Liabilities  (calculated)21,331
+/- 932
Total Stockholder Equity
Common Stock45
Retained Earnings -286,225
Accumulated Other Comprehensive Income 63
Other Stockholders Equity 411,821
Total Stockholder Equity (as reported)125,704
Total Stockholder Equity (calculated)125,704
+/-0
Other
Capital Stock45
Cash and Short Term Investments 120,770
Common Stock Shares Outstanding 44,755
Current Deferred Revenue7,660
Liabilities and Stockholders Equity 173,726
Net Debt 10,195
Net Invested Capital 125,704
Net Working Capital 98,845
Property Plant and Equipment Gross 28,416
Short Long Term Debt Total 21,331



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-03-31
> Total Assets 
0
0
10,151
0
147,049
139,488
280,021
252,701
242,563
223,895
211,379
182,803
175,230
186,692
173,726
173,726186,692175,230182,803211,379223,895242,563252,701280,021139,488147,049010,15100
   > Total Current Assets 
0
0
8,103
142,944
142,944
134,336
278,673
251,257
226,595
202,808
186,612
156,182
149,304
139,094
124,604
124,604139,094149,304156,182186,612202,808226,595251,257278,673134,336142,944142,9448,10300
       Cash And Cash Equivalents 
0
0
8,080
0
142,473
133,477
274,735
247,087
223,355
198,538
179,293
53,059
25,898
14,715
11,136
11,13614,71525,89853,059179,293198,538223,355247,087274,735133,477142,47308,08000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
96,290
116,765
118,252
109,634
109,634118,252116,76596,29000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
598
0
0
0
21
210005980000000000
       Other Current Assets 
0
0
15
0
471
859
84
2,698
1,768
2,798
381
5,361
5,169
4,655
3,813
3,8134,6555,1695,3613812,7981,7682,6988485947101500
   > Long-term Assets 
0
0
2,048
0
4,105
5,152
1,348
1,444
15,968
21,087
24,767
26,621
25,926
47,598
49,122
49,12247,59825,92626,62124,76721,08715,9681,4441,3485,1524,10502,04800
       Property Plant Equipment 
0
0
1,939
1,854
1,854
1,542
1,239
995
15,968
21,087
24,767
26,621
25,926
25,304
24,814
24,81425,30425,92626,62124,76721,08715,9689951,2391,5421,8541,8541,93900
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
22,294
24,308
24,30822,2940000000000000
       Other Assets 
0
0
0
2,251
2,251
3,610
109
449
0
0
0
0
0
0
0
00000004491093,6102,2512,251000
       Deferred Long Term Asset Charges 
0
0
0
0
0
3,501
0
0
0
0
0
0
0
0
0
0000000003,50100000
> Total Liabilities 
0
0
25,796
0
204,637
210,927
18,708
19,187
30,597
35,148
50,555
30,640
29,955
48,746
48,022
48,02248,74629,95530,64050,55535,14830,59719,18718,708210,927204,637025,79600
   > Total Current Liabilities 
0
0
3,689
8,412
8,412
16,837
18,708
19,187
14,916
19,095
31,634
11,601
9,225
28,332
25,759
25,75928,3329,22511,60131,63419,09514,91619,18718,70816,8378,4128,4123,68900
       Short-term Debt 
0
0
615
0
481
325
165
0
0
0
0
1,213
527
1,204
1,232
1,2321,2045271,2130000165325481061500
       Accounts payable 
0
0
1,077
1,266
1,266
1,927
11,951
2,055
7,820
5,509
7,097
4,025
1,305
3,310
3,896
3,8963,3101,3054,0257,0975,5097,8202,05511,9511,9271,2661,2661,07700
       Other Current Liabilities 
0
0
52
4,428
4,428
9,123
266
17,132
7,096
13,586
24,537
6,363
7,393
16,629
12,971
12,97116,6297,3936,36324,53713,5867,09617,1322669,1234,4284,4285200
   > Long-term Liabilities 
0
0
22,107
0
196,225
194,090
12,116
2,055
15,681
16,053
18,921
19,039
20,730
20,414
22,263
22,26320,41420,73019,03918,92116,05315,6812,05512,116194,090196,225022,10700
       Deferred Long Term Asset Charges 
0
0
0
0
0
3,501
0
0
0
0
0
0
0
0
0
0000000003,50100000
       Warrants
0
0
0
0
0
194,023
0
0
0
0
0
0
0
0
0
000000000194,02300000
       Other Liabilities 
0
0
0
2,202
2,202
67
0
0
0
0
0
0
0
0
0
000000000672,2022,202000
       Deferred Long Term Liability 
0
0
0
2,142
2,142
67
0
0
0
0
0
0
0
0
0
000000000672,1422,142000
> Total Stockholder Equity
0
0
-15,645
0
-57,588
-71,439
261,313
233,514
211,966
188,747
160,824
152,163
145,275
137,946
125,704
125,704137,946145,275152,163160,824188,747211,966233,514261,313-71,439-57,5880-15,64500
   Common Stock
0
0
1
10
2
2
32
32
32
32
34
37
39
44
45
4544393734323232322210100
   Retained Earnings Total Equity000-231,678-212,4350-148,6600-91,718-74,88900000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
-21,942
0
0
0
0
0
696
-85
-105
63
63-105-8569600000-21,94200000
   Capital Surplus 
0
0
0
0
0
3,448
352,999
0
360,594
0
373,225
383,108
0
0
0
000383,108373,2250360,5940352,9993,44800000
   Treasury Stock000000000000000
   Other Stockholders Equity 
0
0
97
0
-168,957
3,448
352,999
356,580
360,594
365,049
373,225
383,108
392,900
408,635
411,821
411,821408,635392,900383,108373,225365,049360,594356,580352,9993,448-168,95709700



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-2,000
Gross Profit-2,000-2,000
 
Operating Income (+$)
Gross Profit-2,000
Operating Expense-80,196
Operating Income-82,196-82,196
 
Operating Expense (+$)
Research Development47,886
Selling General Administrative32,610
Selling And Marketing Expenses300
Operating Expense80,19680,796
 
Net Interest Income (+$)
Interest Income6,908
Interest Expense-0
Other Finance Cost-0
Net Interest Income6,908
 
Pretax Income (+$)
Operating Income-82,196
Net Interest Income6,908
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-73,790-90,602
EBIT - interestExpense = -82,196
-73,790
-73,790
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-82,196-73,790
Earnings Before Interest and Taxes (EBITDA)-80,196
 
After tax Income (+$)
Income Before Tax-73,790
Tax Provision-0
Net Income From Continuing Ops-94,294-73,790
Net Income-73,790
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses82,196
Total Other Income/Expenses Net8,406-6,908
 

Technical Analysis of Pyxis Oncology Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Pyxis Oncology Inc. The general trend of Pyxis Oncology Inc is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Pyxis Oncology Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Pyxis Oncology Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 6.18 < 6.85 < 6.92.

The bearish price targets are: 3.6 > 3.4 > 2.87.

Tweet this
Pyxis Oncology Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Pyxis Oncology Inc. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Pyxis Oncology Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Pyxis Oncology Inc. The current macd is -0.01768447.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Pyxis Oncology Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Pyxis Oncology Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Pyxis Oncology Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Pyxis Oncology Inc Daily Moving Average Convergence/Divergence (MACD) ChartPyxis Oncology Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Pyxis Oncology Inc. The current adx is 16.71.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Pyxis Oncology Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Pyxis Oncology Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Pyxis Oncology Inc. The current sar is 6.086432.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Pyxis Oncology Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Pyxis Oncology Inc. The current rsi is 47.83. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Pyxis Oncology Inc Daily Relative Strength Index (RSI) ChartPyxis Oncology Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Pyxis Oncology Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Pyxis Oncology Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Pyxis Oncology Inc Daily Stochastic Oscillator ChartPyxis Oncology Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Pyxis Oncology Inc. The current cci is 2.89057988.

Pyxis Oncology Inc Daily Commodity Channel Index (CCI) ChartPyxis Oncology Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Pyxis Oncology Inc. The current cmo is -7.94263086.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Pyxis Oncology Inc Daily Chande Momentum Oscillator (CMO) ChartPyxis Oncology Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Pyxis Oncology Inc. The current willr is -65.85365854.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Pyxis Oncology Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Pyxis Oncology Inc Daily Williams %R ChartPyxis Oncology Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Pyxis Oncology Inc.

Pyxis Oncology Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Pyxis Oncology Inc. The current atr is 0.54761902.

Pyxis Oncology Inc Daily Average True Range (ATR) ChartPyxis Oncology Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Pyxis Oncology Inc. The current obv is 144,910,927.

Pyxis Oncology Inc Daily On-Balance Volume (OBV) ChartPyxis Oncology Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Pyxis Oncology Inc. The current mfi is 65.62.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Pyxis Oncology Inc Daily Money Flow Index (MFI) ChartPyxis Oncology Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Pyxis Oncology Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-07ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-10BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-23BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside

6.3. Candlestick Patterns

Pyxis Oncology Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Pyxis Oncology Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.825
Ma 20Greater thanMa 504.856
Ma 50Greater thanMa 1005.116
Ma 100Greater thanMa 2003.676
OpenGreater thanClose4.740
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Pyxis Oncology Inc with someone you think should read this too:
  • Are you bullish or bearish on Pyxis Oncology Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Pyxis Oncology Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Pyxis Oncology Inc

I send you an email if I find something interesting about Pyxis Oncology Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Pyxis Oncology Inc.

Receive notifications about Pyxis Oncology Inc in your mailbox!